Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 7, 2012, Pages 1086-1090

  Yasuda, Hiroyuki ^a   De Figueiredo Pontes, Lorena L ^a   Kobayashi, Susumu ^a   Costa, Daniel B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ALK; Anaplastic lymphoma kinase; Crizotinib; Epidermal growth factor receptor; Kinase inhibitor; Lung cancer; Non small cell lung cancer; ROS1; Tyrosine kinase

Indexed keywords

CRIZOTINIB; ERLOTINIB; IMATINIB; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; DOSE RESPONSE; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSLOCATION LINE;

EID: 84862846839     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182570919     Document Type: Article

References (16)

1. Krause DS Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-187. (Pubitemid 41058349)
2. Llovet JM, Ricci S, Mazzaferro V, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
3. Gaughan EM Costa DB. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 2011;3:113-125.
4. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
5. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-4417. (Pubitemid 46815090)
6. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-1075.
7. Pao W Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-180.
8. Keilhack H, Müller M, Böhmer SA, et al. Negative regulation of Ros receptor tyrosine kinase signaling. An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1. J Cell Biol 2001;152:325-334. (Pubitemid 34285602)
9. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 2009;1795:37-52.
10. Gu TL, Deng X, Huang F, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS ONE 2011;6:e15640.
11. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203. (Pubitemid 350235027)
12. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther 2011;5:471-485.
13. Li C, Fang R, Sun Y, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS ONE 2011;6:e28204.
14. Bergethon K, Shaw AT, Ignatius Ou SH, et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. J Clin Oncol 2012;30:863-870.
15. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-381.
16. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011;108:7535-7540.